Rising Investments in Clinical Immunology Drives the Enzyme-Linked Immunosorbent Assay Market, According to New Report by Global Industry Analysts, Inc.

Share Article

GIA launches comprehensive analysis of industry segments, trends, growth drivers, market share, market size and demand forecasts on the Enzyme-Linked Immunosorbent Assay (ELISA) markets. Global market for ELISA is projected to reach US$165 million by 2020, driven by its continued use as a secondary validation technique, and increasing investments in research related to immunology and medicine.

Enzyme-Linked Immunosorbent Assay (ELISA): A Global Strategic Business Report

Follow us on LinkedIn – Enzyme-Linked Immunosorbent Assay (ELISA) or Enzyme Immunoassay (EIA) is a bio-chemical method with immunological applications that is used in the detection of antigens and antibodies in biological samples. ELISA, over the decades, witnessed widespread popularity in the rapidly changing life sciences and drug discovery market. Sales of ELISA products, in the short to medium term, are expected to come largely from the use of ELISA as a secondary validation process by multiplex customers. This is largely due to the quality and established credential of Research ELISA products. Give, its cost effectiveness, ELISA products are preferred by laboratories and researchers dealing with less number of analytes and high sensitivity of assays. Another factor driving growth of ELISA in the immunoassay market is the development of automated platforms. These platforms, specifically designed for running ELISA, offer improved performance, increased productivity, greater sensitivity, better uniformity, improved speed, reduced assay time, cycle time, higher throughput, miniaturization, elimination of time consuming wash steps, and the flexibility to adapt a range of assays/protocol.

In addition, the relatively low penetration of fully automated ELISA offers a solid business case for cellular ELISA manufacturers to tap into the large untapped potential. New technologies, such as the development of new tests that simplify the process of autoantigen extraction and subsequent protein purification, offer additional growth prospects for ELISA. The technique, which involves use of in-vitro labeling of autoantigens for measuring autoantibodies, is expected to find significant application in detecting dermatomyositis and other myositis-specific autoantibodies. Current progress in the area of ELISA tests is being made with the development of NS1 antigen-capture ELISA, which helps efficient clinical management and control of West Nile Virus. These advances could further increase adoption of ELISA.

Despite the opportunities for growth, the market faces numerous challenges in equal measure. The last couple of years witnessed the threat of substitution by new technologies, particularly multiplex proteomic array platforms. The growing preference for multiplex proteomic arrays has been cannibalizing the popularity of ELISA. In addition to the competitive threat posed by multiplex assays, manufacturers have been facing a major challenge in the form of increasing commoditization of ELISA products. Commoditization has intensified pricing pressures for manufacturers. To counter the challenges, manufacturers are targeting niche markets and are focusing on the development of innovative products.

As stated by the new market research report on Enzyme-Linked Immunosorbent Assay (ELISA), the United States represents the largest market for Research ELISA worldwide. Asia-Pacific ranks as the fastest growing regional market with a projected CAGR of 2% over the analysis period. Increasing medical tourism and demand for cost effective biochemical screening technologies are the key factors driving growth in the region.

Major players covered in the report include American Laboratory Products Company (ALPCO), BD Biosciences, BioMérieux SA, Bio-Rad Laboratories Inc., EMD Millipore Corp., Life Technologies Corporation, Ortho-Clinical Diagnostics Inc., R&D Systems Inc., Thermo Fisher Scientific Inc., and ZEUS Scientific Inc.

The research report titled “Enzyme-Linked Immunosorbent Assay (ELISA): A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, issues, drivers, mergers, acquisitions and other strategic industry activities. The report provides market estimates and projections in US dollars for all major geographic markets such as the US, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, Russia and Rest of Europe), Asia-Pacific (China and Rest of Asia-Pacific), Latin America, and Rest of World. Key product segments analyzed for the global and regional markets include ELISA Development Sets & Antibody Pairs, and ELISA Kits.

For more details about this comprehensive market research report, please click here

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes 1500+ full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site: http://www.StrategyR.com/

Global Industry Analysts, Inc. 6150 Hellyer Ave., San Jose CA 95138, USA, All Rights Reserved.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website